Biotech News
Related news
OTLKOutlook2026-08-13 01:45 EST
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
OTLKOutlook2026-08-12 20:01 EST
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
PRQRProQR Therapeutics2026-06-25 10:35 EST
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
TARSTarsus Pharmaceuticals2026-08-06 11:02 EST
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRIXIRIDEX2026-07-20 11:00 EST
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
LENZLenz Therapeutics Inc2026-07-06 12:15 EST
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LCTXLineage Cell Therapeutics2026-09-08 12:00 EST
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
OCSOculis2026-08-10 07:30 EST
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
LENZLenz Therapeutics Inc2026-08-04 20:05 EST
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
LCTXLineage Cell Therapeutics2026-07-30 12:00 EST
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-10-06 13:20 EST
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
OTLKOutlook2026-10-01 13:01 EST
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Stock data
- Close
- 0.57 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States